Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.

TROPHIC TWITTER FEED

Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

This week @HerantisPharma announced Phase 1-2 topline results from the #ClinicalTrial testing its proprietary neuroprotective factor & novel drug candidate, CDNF in #ParkinsonsDisease patients. See here for the full announcement: https://t.co/sdYbiM8B3b

Herantis is hosting a #Webcast at 10:00 AM CET today to discuss the Phase 1-2 CDNF #ClinicalTrial results. To listen in, please register here: https://t.co/060S9jaNFd #ParkinsonsDisease

Another year, another scone! #HappyBirthday to our wonderful Vice President, @StephAmaSing! In true Trophic tradition, we had a great time celebrating over a tasty Italian lunch followed by homemade baked goods. Of course, we were not the only ones eyeing the treats… #AllesGute!

Load More...